S&P 5007,533.77▼0.5% Nasdaq25,881.95▼1.5% Dow52,552.97▼0.2% Russell 2K2,974.57▼0.1% 10-Yr4.57%+2bp VIX16.73+1.06 WTI$79.00▼0.8% Gold$3,981.40▼1.6% EUR/USD1.145▼0.2% BTC$66,570▲2.0% Nikkei68,752▲1.5%
At close · Thu, Jul 16, 2026
Daily Market Updates.

Global Markets

Home›Global Markets›China›U.S. biotech firm turns to Hong Kong for its initial l…

U.S. biotech firm turns to Hong Kong for its initial listing

The move reflects Hong Kong’s expanding investor base and its closeness to Chinese pharmaceutical partners.

Reported · Written up by our desk · China

CNBC World reports that one U.S. biotech firm is choosing Hong Kong for its first listing rather than proceeding immediately with a U.S. debut.

The outlet links the decision to a broader trend among global biotech companies that are increasingly drawn to Hong Kong, citing its growing investor base.

CNBC World also points to Hong Kong’s proximity to Chinese pharmaceutical partners as another factor behind the shift.

← Newer storyUS says Iran war costs have reached $37.5 billion

More like this

Global MarketsNike streamlines its China online business by cutting distributors
Global MarketsChina’s regulator approves novel narcolepsy type 1 therapy first
Global MarketsChina’s EV model highlights how emerging markets could build champions
Global MarketsChina’s national team steps in with buybacks to calm A-share swings
Global MarketsZhipu shares jump after completion of 1-gigawatt AI data center

Sources

CNBC WorldWall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.